Rhythm Pharmaceuticals (RYTM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Key Insights
Critical company metrics and information
Share Price
$57.60Market Cap
$3.54 BillionTotal Outstanding Shares
61.46 Million SharesTotal Employees
226Dividend
No dividendIPO Date
October 5, 2017SIC Description
Pharmaceutical PreparationsHomepage
http://www.rhythmtx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-46.69 Million |
Net Cash Flow From Operating Activities | $-124.42 Million |
Net Cash Flow, Continuing | $-15.77 Million |
Net Cash Flow From Investing Activities | $-46.69 Million |
Net Cash Flow From Financing Activities, Continuing | $155.34 Million |
Net Cash Flow From Operating Activities, Continuing | $-124.42 Million |
Net Cash Flow From Financing Activities | $155.34 Million |
Net Cash Flow | $-15.77 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $365.23 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-261.57 Million |
Income/Loss From Continuing Operations After Tax | $-258.94 Million |
Basic Average Shares | $182.89 Million |
Basic Earnings Per Share | $-4.33 |
Costs And Expenses | $378.05 Million |
Selling, General, and Administrative Expenses | $138.55 Million |
Preferred Stock Dividends And Other Adjustments | $2.63 Million |
Net Income/Loss Attributable To Parent | $-258.94 Million |
Operating Income/Loss | $-265.51 Million |
Diluted Earnings Per Share | $-4.32 |
Gross Profit | $99.72 Million |
Net Income/Loss | $-258.94 Million |
Diluted Average Shares | $122.32 Million |
Research and Development | $226.68 Million |
Revenues | $112.53 Million |
Cost Of Revenue | $12.81 Million |
Income/Loss From Continuing Operations Before Tax | $-258.31 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Benefits Costs and Expenses | $370.81 Million |
Income Tax Expense/Benefit | $631,000.00 |
Nonoperating Income/Loss | $7.24 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $2.63 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $11.21 Million |
Other Current Assets | $28.06 Million |
Assets | $363.57 Million |
Temporary Equity Attributable To Parent | $141.48 Million |
Other Non-current Assets | $22.43 Million |
Current Assets | $340.34 Million |
Noncurrent Liabilities | $113.27 Million |
Temporary Equity | $141.48 Million |
Inventory | $13.89 Million |
Noncurrent Assets | $23.23 Million |
Liabilities And Equity | $363.57 Million |
Cash | $298.39 Million |
Fixed Assets | $801,000.00 |
Other Current Liabilities | $92.72 Million |
Equity | $11.21 Million |
Accounts Payable | $4.89 Million |
Current Liabilities | $97.61 Million |
Liabilities | $210.88 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.